About Us
Amorsa is dedicated to improving the health and well-being of patients affected by neuropsychiatric disorders.
Technology Platform
Building on ketamine’s proven success as a rapid-acting antidepressant, Amorsa is developing novel oral therapeutic agents based on proprietary ketamine analogs.
Target Applications
Pioneering breakthrough treatments for neuropsychiatric disorders including treatment-resistant depression, PTSD and obsessive-compulsive disorder.
Latest News
Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Deuterated Norketamine and Related Compounds
Southborough, MA, February 14, 2019 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments...
Amorsa Therapeutics Appoints Jeffrey Wiesen to Board of Directors
Southborough, MA, June 1, 2018 – Amorsa Therapeutics Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments for...
Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Oral Compositions of Ketamine and Related Compounds
Southborough, MA, January 9, 2018 – Amorsa Therapeutics, Inc., a neuropharmaceutical company pioneering the development of breakthrough treatments...